61:
660:"Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis"
319:
Gandhi, Namita A.; Bennett, Brandy L.; Graham, Neil M. H.; Pirozzi, Gianluca; Stahl, Neil; Yancopoulos, George D. (2016-01-01).
108:
57:
658:
Khan, Asif; Gouia, Imène; Kamat, Siddhesh; Ortiz, Benjamin; Johnson, Robert; Siddall, James; Small, Mark (2020-09-07).
721:
146:
20:
259:"Host protective roles of type 2 immunity: Parasite killing and tissue repair, flip sides of the same coin"
152:
Persons with one type 2 inflammatory disease are more likely to have other type 2 inflammatory diseases.
711:
492:
167:
687:
534:
491:
Akdis, Cezmi A.; Arkwright, Peter D.; Brüggen, Marie-Charlotte; Busse, William; Gadina, Massimo;
413:
356:
376:"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation"
679:
640:
622:
583:
526:
518:
470:
452:
405:
397:
348:
340:
296:
278:
136:
124:
115:
to the site of inflammation, while IL-5 promotes both eosinophil trafficking and production.
671:
630:
614:
573:
565:
508:
460:
444:
387:
332:
286:
270:
716:
495:; Kabashima, Kenji; Mitamura, Yasutaka; Vian, Laura; Wu, Jianni; Palomares, Oscar (2020).
38:
30:
675:
635:
602:
578:
553:
465:
432:
291:
258:
97:
81:
53:
49:
34:
659:
705:
691:
538:
417:
93:
89:
69:
37:, but a dysregulation of the type 2 inflammatory response has been implicated in the
160:
Several medicines have been developed that target mediators of type 2 inflammation:
360:
207:
202:
182:
172:
227:
187:
141:
274:
618:
374:
Hong, Haiyu; Liao, Shumin; Chen, Fenghong; Yang, Qintai; Wang, De-Yun (2020).
232:
192:
112:
683:
626:
522:
456:
401:
344:
282:
217:
644:
587:
530:
474:
409:
352:
300:
320:
65:
569:
513:
496:
392:
375:
131:
448:
336:
552:
Hulse, K. E.; Stevens, W. W.; Tan, B. K.; Schleimer, R. P. (2015).
321:"Targeting key proximal drivers of type 2 inflammation in disease"
433:"Type 2 inflammation in asthma — present in most, absent in many"
77:
103:
IL-4 further drives CD4+ T cell differentiation towards the T
111:
to IgE in B cells. IL-4 and IL-13 stimulate trafficking of
33:. Its physiological function is to defend the body against
603:"The Immunologic Mechanisms of Eosinophilic Esophagitis"
257:
Allen, Judith E.; Sutherland, Tara E. (2014-08-01).
123:Type 2 inflammation has been implicated in several
64:released from damaged epithelial cells. These
601:Hill, David A.; Spergel, Jonathan M. (2016).
8:
634:
577:
512:
464:
391:
290:
497:"Type 2 immunity in the skin and lungs"
246:
7:
486:
484:
314:
312:
310:
252:
250:
558:Clinical & Experimental Allergy
142:Chronic sinusitis with nasal polyps
676:10.1183/13993003.congress-2020.232
607:Current Allergy and Asthma Reports
14:
554:"Pathogenesis of nasal polyposis"
68:mediate the activation of type 2
88:2 cells and ILC2 cells secrete
214:Dual IL-4 and IL-13 blockers:
119:Dysregulation in human disease
1:
325:Nature Reviews Drug Discovery
664:European Respiratory Journal
78:type 2 innate lymphoid cells
738:
275:10.1016/j.smim.2014.06.003
18:
16:Pattern of immune response
619:10.1007/s11882-015-0592-3
437:Nature Reviews Immunology
199:IL-13-specific blockers:
179:IL-5-specific blockers:
164:IL-4-specific blockers:
147:Eosinophilic esophagitis
21:type II hypersensitivity
19:Not to be confused with
156:Pharmacological targets
431:Fahy, John V. (2015).
263:Seminars in Immunology
107:2 subtype and induces
41:of several diseases.
493:Guttman-Yassky, Emma
27:Type 2 inflammation
80:(ILC2 cells), and
722:Atopic dermatitis
670:(suppl 64): 232.
570:10.1111/cea.12472
514:10.1111/all.14318
393:10.1111/all.14526
386:(11): 2794–2804.
137:Atopic dermatitis
109:isotype switching
45:Molecular biology
729:
696:
695:
655:
649:
648:
638:
598:
592:
591:
581:
549:
543:
542:
516:
507:(7): 1582–1605.
488:
479:
478:
468:
428:
422:
421:
395:
371:
365:
364:
316:
305:
304:
294:
254:
125:chronic diseases
29:is a pattern of
737:
736:
732:
731:
730:
728:
727:
726:
702:
701:
700:
699:
657:
656:
652:
600:
599:
595:
551:
550:
546:
490:
489:
482:
449:10.1038/nri3786
430:
429:
425:
373:
372:
368:
337:10.1038/nrd4624
318:
317:
308:
256:
255:
248:
243:
158:
121:
106:
87:
82:dendritic cells
75:
47:
39:pathophysiology
31:immune response
24:
17:
12:
11:
5:
735:
733:
725:
724:
719:
714:
704:
703:
698:
697:
650:
593:
564:(2): 328–346.
544:
480:
423:
366:
306:
269:(4): 329–340.
245:
244:
242:
239:
238:
237:
236:
235:
230:
224:IgE-blockers:
222:
221:
220:
212:
211:
210:
205:
197:
196:
195:
190:
185:
177:
176:
175:
170:
157:
154:
150:
149:
144:
139:
134:
120:
117:
104:
85:
73:
70:T helper cells
46:
43:
15:
13:
10:
9:
6:
4:
3:
2:
734:
723:
720:
718:
715:
713:
710:
709:
707:
693:
689:
685:
681:
677:
673:
669:
665:
661:
654:
651:
646:
642:
637:
632:
628:
624:
620:
616:
612:
608:
604:
597:
594:
589:
585:
580:
575:
571:
567:
563:
559:
555:
548:
545:
540:
536:
532:
528:
524:
520:
515:
510:
506:
502:
498:
494:
487:
485:
481:
476:
472:
467:
462:
458:
454:
450:
446:
442:
438:
434:
427:
424:
419:
415:
411:
407:
403:
399:
394:
389:
385:
381:
377:
370:
367:
362:
358:
354:
350:
346:
342:
338:
334:
330:
326:
322:
315:
313:
311:
307:
302:
298:
293:
288:
284:
280:
276:
272:
268:
264:
260:
253:
251:
247:
240:
234:
231:
229:
226:
225:
223:
219:
216:
215:
213:
209:
206:
204:
201:
200:
198:
194:
191:
189:
186:
184:
181:
180:
178:
174:
171:
169:
166:
165:
163:
162:
161:
155:
153:
148:
145:
143:
140:
138:
135:
133:
130:
129:
128:
126:
118:
116:
114:
110:
101:
99:
95:
91:
83:
79:
71:
67:
63:
59:
55:
51:
44:
42:
40:
36:
32:
28:
22:
667:
663:
653:
610:
606:
596:
561:
557:
547:
504:
500:
443:(1): 57–65.
440:
436:
426:
383:
379:
369:
331:(1): 35–50.
328:
324:
266:
262:
208:Tralokinumab
203:Lebrikizumab
183:Benralizumab
173:Pascolizumab
168:Altrakincept
159:
151:
122:
102:
48:
26:
25:
228:Ligelizumab
188:Mepolizumab
113:eosinophils
712:Immunology
706:Categories
241:References
233:Omalizumab
193:Reslizumab
76:2 cells),
692:229017279
684:0903-1936
627:1529-7322
539:216075178
523:1398-9995
457:1474-1733
418:220908481
402:1398-9995
345:1474-1784
283:1044-5323
218:Dupilumab
66:cytokines
35:helminths
645:26758862
613:(2): 9.
588:25482020
531:32319104
475:25534623
410:32737888
353:26471366
301:25028340
62:alarmins
636:4913464
579:4422388
501:Allergy
466:4390063
380:Allergy
361:2421591
292:4179909
717:Asthma
690:
682:
643:
633:
625:
586:
576:
537:
529:
521:
473:
463:
455:
416:
408:
400:
359:
351:
343:
299:
289:
281:
132:Asthma
56:, and
688:S2CID
535:S2CID
414:S2CID
357:S2CID
98:IL-13
54:IL-33
50:IL-25
680:ISSN
641:PMID
623:ISSN
584:PMID
527:PMID
519:ISSN
471:PMID
453:ISSN
406:PMID
398:ISSN
349:PMID
341:ISSN
297:PMID
279:ISSN
96:and
94:IL-5
90:IL-4
60:are
58:TSLP
672:doi
631:PMC
615:doi
574:PMC
566:doi
509:doi
461:PMC
445:doi
388:doi
333:doi
287:PMC
271:doi
84:. T
708::
686:.
678:.
668:56
666:.
662:.
639:.
629:.
621:.
611:16
609:.
605:.
582:.
572:.
562:45
560:.
556:.
533:.
525:.
517:.
505:75
503:.
499:.
483:^
469:.
459:.
451:.
441:15
439:.
435:.
412:.
404:.
396:.
384:75
382:.
378:.
355:.
347:.
339:.
329:15
327:.
323:.
309:^
295:.
285:.
277:.
267:26
265:.
261:.
249:^
127::
100:.
92:,
72:(T
52:,
694:.
674::
647:.
617::
590:.
568::
541:.
511::
477:.
447::
420:.
390::
363:.
335::
303:.
273::
105:h
86:h
74:h
23:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.